Renal vascular sclerosis is associated with inherited thrombophilias

Kidney International

Volumn 70, Issue 4, 2006, Pages 743-750

  Goforth, R L ^a   Rennke, H ^b   Sethi, S ^c  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MAYO CLINIC   (United States)

Author keywords

Factor V Leiden; Methylenetetrahydrofolate reductase gene; Prothrombin gene; Thrombophilia; Vascular sclerosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERTENSION; KIDNEY BIOPSY; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NEPHROSCLEROSIS; PRIORITY JOURNAL; SMOKING; THROMBOPHILIA;

ADULT; AGED; BIOPSY; DIABETES MELLITUS; FACTOR V; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; KIDNEY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; MUTATION; NEPHROSCLEROSIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; RENAL ARTERY; RISK FACTORS; SCLEROSIS; SMOKING; THROMBOPHILIA;

EID: 33747048633     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001551     Document Type: Article

References (27)

1. Press RD, Baeur KA, Kujovich JL et al. Clinical utility of factor V Leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med 2002; 126: 1304-1318.
2. Hillarp A, Zoller B, Dahlback B. Activated protein C resistance as a basis for venous thrombosis. Am J Med 1996; 101: 534-540.
3. Schafer AI. Hypercoagulable states: molecular genetics to clinical practice. Lancet 1994; 344: 1739-1742.
4. Laffan M, Tuddenham E. Science, medicine, and the future: assessing thrombotic risk. BMJ 1998; 317: 520-523.
5. Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Haemostasis and Thrombosis. 3rd edn. Churchill Livingstone: Edinburgh, 1994: 1477, pp.
6. Lane DA, Mannucci P, Bauer KA et al. Inherited thrombophilia: Part 1. Thromb Haemost 1996; 76: 651-662.
7. Franco RF, Reitsma PH. Gene polymorphisms of the haemostatic system and the risk of arterial thrombotic disease. Br J Haematol 2001; 115: 491-506.
8. Sun X, Evatt B, Griffin J. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia. Blood 1994; 83: 3120-3125.
9. Tosetto A, Missiaglia E, Frezzato M, Rodeghiero F. The VITA project: prothrombin G20210A mutation and venous thromboembolism in the general population. Thromb Haemost 1999; 82: 1395-1398.
10. Gehring NH, Fred U, Neu-Yilik G et al. Increased efficiency of mRNA 3′ end formation: a new genetic mechanism contributing to hereditary thrombophilia. Nat Genet 2001; 28: 389-392.
11. Cattaneo M, Chantarangkul V, Taioli E et al. The G20210A mutation of the prothrombin gene in patients with previous first episodes of deep-vein thrombosis: prevalence and association with factor V G1691A, methylenetetrahydrofolate reductase C677T and plasma prothrombin levels. Thrombosis Res 1999; 93: 1-8.
12. Kang SS, Wong PW, Susmano A et al. Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991; 48: 536-545.
13. Frosst P, Blom HJ, Milos R et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
14. Jacques PF, Bostom AG, Williams RR et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996; 93: 7-9.
15. Kanwar Y, Manaligod J, Wong P. Morphologic studies in a patient with homocystinuria due to 5, 10- methylenetetrahydrofolate reductase deficiency. Pediatr Res 1976; 10: 598-609.
16. Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. Circulation 1999; 99: 999-1004.
17. Ridker PM, Hennekens CH, Selhub J et al. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-1782.
18. Neugebauer S, Baba T, Watanabe T. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998; 352: 454.
19. Moczulski D, Fojcik H, Zukowska-Szczechowska E et al. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant 2003; 18: 1535-1540.
20. Ksiazek PA, Bednarek-Skublewska A, Buraczynska M. The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus. Med Sci Monit 2004; 10: BR47-BR51.
21. Friedman AN, Hunsicker LG, Selhub J et al. Total plasma homocysteine and arteriosclerotic outcomes in type 2 diabetes with nephropathy. J Am Soc Nephrol 2005; 16: 3397-3402.
22. Pirani CL. Evaluation of kidney biopsy specimens. In: Tisher CC, Brenner BM (eds). Renal Pathology with Clinical and Functional Correlations. J.B. Lippincott Company: Philadelphia, 1989, pp 11-42.
23. Hezard N, Cornillet P, Droulle C et al. Factor V Leiden: detection in whole blood by ASA PCR using an additional mismatch in antepenultimate position. Thrombosis Res 1997; 88: 59-66.
24. Poort SR Bertina RM, Vos HL. Rapid detection of the prothrombin 20210 A variation by allele specific PCR. Thromb Haemost 1997; 78: 1157-1158.
25. Hezard N, Cornillet P, Gillot L et al. Multiplex ASA PCR for a simultaneous determination of factor V Leiden gene, G- > A 20210 prothrombin gene and C- > T 677 MTHFR gene mutations. Thromb Haemost 1998; 79: 1054-1055.
26. Reitsma PH, Bertina RM, Ploos van Amstel JK et al. The putative factor IX gene promoter in hemophilia B Leyden. Blood 1988; 72: 1074-1076.
27. Gardner MJ, Altman DG. Confidence intervals rather than P values. In: Altman DG et al. (eds). Statistics with Confidence: Confidence Intervals and Statistical Guidelines. BMJ Books: London, 2000, pp 3-5.